Most Read Articles
2 days ago
Nontraditional eating patterns, such as skipped or delayed breakfast, are potentially linked to mood disorders, according to a study.
06 Jan 2021
Optimal therapy for heart failure with reduced ejection fraction (HFrEF) remains underused due to clinical inertia. A recent post hoc analysis of the DAPA-HF trial serves as a call for change, as patients with longer duration of HFrEF survivorship were found to have higher rates of worsening heart failure (HF) and cardiovascular (CV) death. Importantly, benefits of the sodium-glucose co-transporter 2 (SGLT2) inhibitor, dapagliflozin, on these outcomes were shown to be consistent across the spectrum of HF duration, with the greatest absolute benefit seen in longest-duration HF.
Jairia Dela Cruz, 18 Jan 2021
For inflammatory bowel disease (IBD) patients, smoking cigarettes or just being exposed to secondhand smoke raises the risk of developing colorectal neoplasia, a study has found.
Audrey Abella, 15 Jan 2021
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.

Sacubitril/valsartan reduces NT-proBNP vs RAS inhibitors in HFpEF

29 Dec 2020

In patients with heart failure with preserved ejection fraction (HFpEF), sacubitril/valsartan provides significantly greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) than optimal individualized medical therapy, while improvements in functional capacity are similar between the two groups, results of the PARALLAX trial have shown.

The trial’s first primary endpoint of change in plasma NT-proBNP from baseline to 12 weeks was 16.4 percent greater in patients randomized to receive sacubitril/valsartan vs optimal individualized medical therapy (enalapril, valsartan, or placebo for patients not on a renin-angiotensin system [RAS] inhibitor) (p<0.0001). [Pieske B, et al, ESC 2020]

However, the second primary endpoint of change in 6-minute walk distance from baseline to 24 weeks did not differ significantly between the two groups (mean difference, -2.5 m; p=0.79).

Rates of serious adverse events were similar between the two groups except for HF events, which were more common with individualized medical therapy. In a post hoc analysis, sacubitril/valsartan significantly reduced the risk of HF hospitalization by 50 percent (p=0.005) vs individualized medical therapy. Patients in the sacubitril/valsartan group also had a significantly lower decline in renal function at 24 weeks.


 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Nontraditional eating patterns, such as skipped or delayed breakfast, are potentially linked to mood disorders, according to a study.
06 Jan 2021
Optimal therapy for heart failure with reduced ejection fraction (HFrEF) remains underused due to clinical inertia. A recent post hoc analysis of the DAPA-HF trial serves as a call for change, as patients with longer duration of HFrEF survivorship were found to have higher rates of worsening heart failure (HF) and cardiovascular (CV) death. Importantly, benefits of the sodium-glucose co-transporter 2 (SGLT2) inhibitor, dapagliflozin, on these outcomes were shown to be consistent across the spectrum of HF duration, with the greatest absolute benefit seen in longest-duration HF.
Jairia Dela Cruz, 18 Jan 2021
For inflammatory bowel disease (IBD) patients, smoking cigarettes or just being exposed to secondhand smoke raises the risk of developing colorectal neoplasia, a study has found.
Audrey Abella, 15 Jan 2021
A pilot telemedicine initiative may be an alternative for facilitating delivery of intravenous iron (IVI) for individuals requiring iron supplementation.